Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Abstract Background Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on survival outcomes in patients with hormone recepto...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, Xianchen Liu, Jack Mardekian, Lynn McRoy, Rachel M. Layman, Birol Emir, Mylin A. Torres, Hope S. Rugo, Richard S. Finn
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2021-03-01
Edice:	Breast Cancer Research
Témata:	HR+/HER2− Metastatic breast cancer Palbociclib Letrozole Real-world data Comparative effectiveness
On-line přístup:	https://doi.org/10.1186/s13058-021-01409-8
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!